Syndax Pharmaceuticals (STU:1T3) ROCE % : -73.93% (As of Dec. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Syndax Pharmaceuticals ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Syndax Pharmaceuticals's annualized ROCE % for the quarter that ended in Dec. 2024 was -73.93%.

Syndax Pharmaceuticals ROCE % Historical Data

The historical data trend for Syndax Pharmaceuticals's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Syndax Pharmaceuticals ROCE % Chart

Syndax Pharmaceuticals Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

ROCE %

Get a 7-Day Free Trial

-42.76

7.77

-33.60

-40.35

-54.39

Syndax Pharmaceuticals Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
ROCE %	Get a 7-Day Free Trial															-62.78	-55.37	-59.02	-82.61	-73.93

Syndax Pharmaceuticals ROCE % Calculation

Syndax Pharmaceuticals's annualized ROCE % for the fiscal year that ended in Dec. 2024 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2024 )		(A: Dec. 2023 )		(A: Dec. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2024 )		(A: Dec. 2023 )		(A: Dec. 2024 )
	=	-299.707	/	( ( (562.011 - 53.274)	+	(692.199 - 98.889) )	/ 2 )
	=	-299.707	/	( (508.737	+	593.31)	/ 2 )
	=	-299.707	/	551.0235
	=	-54.39 %

Syndax Pharmaceuticals's ROCE % of for the quarter that ended in Dec. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2024 )		(Q: Sep. 2024 )		(Q: Dec. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2024 )		(Q: Sep. 2024 )		(Q: Dec. 2024 )
	=	-341.368	/	( ( (383.656 - 53.499)	+	(692.199 - 98.889) )	/ 2 )
	=	-341.368	/	( ( 330.157	+	593.31 )	/ 2 )
	=	-341.368	/	461.7335
	=	-73.93 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2024) EBIT data.

Syndax Pharmaceuticals (STU:1T3) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Syndax Pharmaceuticals ROCE % Related Terms

Thank you for viewing the detailed overview of Syndax Pharmaceuticals's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Syndax Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Syndax Pharmaceuticals Inc (STU:1T3) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

SNDX:USA

Address

730 Third Avenue, 9th Floor, New York, NY, USA, 10017

Website

https://www.syndax.com

Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.

Syndax Pharmaceuticals Headlines

No Headlines